201 related articles for article (PubMed ID: 7203726)
1. Pharmacokinetics and metabolism of theophylline in patients with liver diseases.
Staib AH; Schuppan D; Lissner R; Zilly W; von Bomhard G; Richter E
Int J Clin Pharmacol Ther Toxicol; 1980 Nov; 18(11):500-2. PubMed ID: 7203726
[TBL] [Abstract][Full Text] [Related]
2. [Drug metabolism in patients with liver disease (author's transl)].
Richter E; Epping J; Fuchshofen-Röckel M; Heusler H; Zilly W
Leber Magen Darm; 1980 Oct; 10(5):234-40. PubMed ID: 7464410
[TBL] [Abstract][Full Text] [Related]
3. Liver dysfunction markedly decreases the inhibition of cytochrome P450 1A2-mediated theophylline metabolism by fluvoxamine.
Orlando R; Padrini R; Perazzi M; De Martin S; Piccoli P; Palatini P
Clin Pharmacol Ther; 2006 May; 79(5):489-99. PubMed ID: 16678550
[TBL] [Abstract][Full Text] [Related]
4. [Clinico-prognostic significance of plasma cortisol half-life(after intravenous administration ) during acute and chronic hepatic diseases].
Del Prete S; Malacco E; Bonzi G; Natelli A; Roncoroni S; Jalanbo H
Minerva Med; 1975 Mar; 66(22):1051-7. PubMed ID: 1124151
[TBL] [Abstract][Full Text] [Related]
5. [Anti-rheumatic therapy in patients with liver diseases. Plasma levels of diclofenac and elimination of diclofenac and metabolites in urine of patients with liver disease].
Zimmerer J; Tittor W; Degen P
Fortschr Med; 1982 Sep; 100(36):1683-8. PubMed ID: 7141370
[TBL] [Abstract][Full Text] [Related]
6. Enhanced renal clearance of uric acid in hepatic cirrhosis.
Higuchi T; Nakamura T; Uchino H
Isr J Med Sci; 1981 Nov; 17(11):1015-8. PubMed ID: 7319788
[TBL] [Abstract][Full Text] [Related]
7. [Metabolism of hexobarbital in patients with acute hepatitis and cirrhosis (author's transl)].
Richter E; Gallenkamp H; Keller B; Brachtel D; Zilly W; Breimer DD
Z Gastroenterol; 1977 Jun; 15(6):381-8. PubMed ID: 888488
[TBL] [Abstract][Full Text] [Related]
8. Drug disposition in liver disease.
Fruncillo RJ
Am Fam Physician; 1982 Dec; 26(6):167-9. PubMed ID: 7148640
[No Abstract] [Full Text] [Related]
9. [Comparative study on the elimination of pindolol (visken) and antipyrin in patients with liver diseases].
Ohnhaus EE; Münch U; Meier J
Schweiz Med Wochenschr; 1976 Dec; 106(49):1748-50. PubMed ID: 1013699
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics of trapidil (Rocornal) in patients with chronic liver disease.
Berndt A; Pönicke K; Weiss M
Int J Clin Pharmacol Ther Toxicol; 1992 Nov; 30(11):492-3. PubMed ID: 1490801
[TBL] [Abstract][Full Text] [Related]
11. Influence of hepatic insufficiency in pharmacokinetics of drugs: example for an anthranilic diuretic.
Dreux C; Passa P; Halter D
Methods Find Exp Clin Pharmacol; 1979 Dec; 1(5):289-96. PubMed ID: 552592
[TBL] [Abstract][Full Text] [Related]
12. Gender differences in hepatic induction and inhibition of theophylline pharmacokinetics and metabolism.
Jennings TS; Nafziger AN; Davidson L; Bertino JS
J Lab Clin Med; 1993 Aug; 122(2):208-16. PubMed ID: 8340707
[TBL] [Abstract][Full Text] [Related]
13. Altered kinetics of etozolin and its active metabolite ozolinone in hepatitis and hepatic cirrhosis with ascites.
Knauf H; Missmahl M; Schölmerich J; Gerok W; Mutschler E
Arzneimittelforschung; 1987 Dec; 37(12):1385-8. PubMed ID: 3449068
[TBL] [Abstract][Full Text] [Related]
14. Biotransformation and uric acid lowering effect of benzbromarone in patients with liver cirrhosis - evidence for active benzbromarone metabolites?
Walter-Sack I; de Vries JX; von Bubnoff A; Pfleilschifter V; Raedsch R
Eur J Med Res; 1995 Oct; 1(1):16-20. PubMed ID: 9392688
[TBL] [Abstract][Full Text] [Related]
15. [Peculiarities of the pharmacokinetics and pharmacodynamics of theophylline in children].
Berdel D; Heimann G
Wien Klin Wochenschr; 1984 Aug; 96(16):616-21. PubMed ID: 6516414
[TBL] [Abstract][Full Text] [Related]
16. [Metabolism of phenylbutazone in the liver (author's transl)].
González Macías J; De Castro del Pozo S
Med Klin; 1976 Sep; 71(36):1434-8. PubMed ID: 958107
[TBL] [Abstract][Full Text] [Related]
17. Effect of age and parenchymal liver disease on the disposition and elimination of chlordiazepoxide (librium).
Roberts RK; Wilkinson GR; Branch RA; Schenker S
Gastroenterology; 1978 Sep; 75(3):479-85. PubMed ID: 680505
[TBL] [Abstract][Full Text] [Related]
18. Half-life time or clearance of indocyanine green in patients with liver disease.
Gilmore IT; Marigold JH; Thompson RP
Hepatogastroenterology; 1982 Apr; 29(2):55-7. PubMed ID: 7084884
[TBL] [Abstract][Full Text] [Related]
19. Metabolism of a prednisolone compound in human under normal and pathological conditions.
Fehér T; Koref O; Tankó A; Bodrogi L; Poteczin E
Arzneimittelforschung; 1975 Aug; 25(8):1314-7. PubMed ID: 52365
[TBL] [Abstract][Full Text] [Related]
20. Caffeine clearance by two point analysis: a measure of liver function in chronic liver disease.
Wittayalertpanya S; Israsena S; Thamaree S; Tongnopnoua P; Komolmit P
Tokai J Exp Clin Med; 1996 Dec; 21(4-6):195-201. PubMed ID: 9300980
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
